Subcutaneous Cagrilintide, Semaglutide Shows Significant Weight Loss in Type 2 Diabetes Trial US$ 22.58 Min. order: 1 piece ★★★★★ 4.2 (21 reviews) Sold : Login>>
Novo Nordisk advances obesity candidate to late-stage program after weight loss of less than 12% US$ 23.78 Min. order: 1 piece ★★★★★ 5.0 (162 reviews) Sold : Login>>
Ph B. Nova Bpc-157 Pro, Novo Composto Protetor 157, 60 US$ 27.89 Min. order: 1 piece ★★★★★ 4.6 (17 reviews) Sold : Login>>
Novo Nordisk presents phase 3 data for next-generation amylin cagrilintide, leading to advancement into dedicated clinical programme US$ 27.05 Min. order: 1 piece ★★★★★ 5.0 (164 reviews) Sold : Login>>
Novo Nordisk files for FDA approval for CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues US$ 23.01 Min. order: 1 piece ★★★★★ 4.1 (172 reviews) Sold : Login>>